Samsung Biologics signs KRW 1.8T contract deal

The second-largest contract in the company's history

Singed a CMO agreement with a U.S.-based pharmaceutical company..,this year's cumulative contract value amounted to KRW 5.2435 trillion

Samsung Biologics announced on September 9 that it has signed a Contract Manufacturing Organization (CMO) agreement worth $1.294 billion (approximately KRW 1.800 trillion) with a U.S.-based pharmaceutical company

Samsung Biologics

This contract is the second-largest one in the company's history, following a deal worth approximately KRW 2 trillion with a European pharmaceutical company in January.

 

The contract is set to run until December 31, 2029.

 

The client and product name have not been disclosed due to confidentiality clauses.

 

Samsung Biologics' cumulative contract value for this year has reached KRW 5.2435 trillion.

 

In just eight months, the company has nearly matched its total contract value from last year (KRW 5.4035 trillion).

 

Its total cumulative contract value since its founding has now exceeded $20 billion.

 

Samsung Biologics said, "Even as business uncertainties for the entire bio-industry, such as a global economic slowdown and tariff impacts, continue to grow, our consecutive large-scale contracts once again prove our competitiveness and the market's trust in us." Samsung Biologics is expanding its production capacity to meet the increasing demand for biopharmaceuticals.

 

Its fifth plant, a 180,000-liter production facility that integrates the best practices from plants 1-4, began full-scale operation in April.

 

With this, Samsung Biologics has secured a total production capacity of 784,000 liters, making it the world's largest.

 

Samsung Biologics has obtained a total of 382 manufacturing approvals from major global regulatory agencies in the U.S., Europe, and Japan.

 

The company stated that the number of approvals continues to increase with its expanding production capacity, and its pass rate for regulatory audits remains among the highest in the industry.

 

Samsung Biologics added, "We are continuously expanding our customer base by securing numerous new contracts across the globe this year, including in the U.S., Europe, and Asia, based on our core competitiveness of overwhelming production capacity, quality, and various track records."